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ABSTRACT The crystallographic structure of human coagulation factor VIIa/tissue factor complex bound with calcium ions
was used to model the solution structure of the light chain of factor VIIa (residues 1–142) in the absence of tissue factor. The
Amber force field in conjunction with the particle mesh Ewald summation method to accommodate long-range electrostatic
interactions was used in the trajectory calculations. The estimated TF-free solution structure was then compared with the
crystal structure of factor VIIa/tissue factor complex to estimate the restructuring of factor VIIa due to tissue factor binding.
The solution structure of the light chain of factor VIIa in the absence of tissue factor is predicted to be an extended domain
structure similar to that of the tissue factor-bound crystal. Removal of the EGF1-bound calcium ion is shown by simulation
to lead to minor structural changes within the EGF1 domain, but also leads to substantial relative reorientation of the Gla and
EGF1 domains.
INTRODUCTION
The zymogen factor VII has no activity in its native form in
the circulating blood. Activation occurs upon contact with
tissue factor (TF), exposed by vascular injury. Once formed,
this complex rapidly initiates blood coagulation by proteo-
lytically activating its substrates, factor IX and X, leading to
thrombin formation and a fibrin clot. Although earlier stud-
ies (Zur and Nemerson, 1978; Jesty and Morrison, 1983)
reported that the single chain factor VII demonstrates con-
siderable activity toward substrates, recent experimental
data (Wildgoose et al., 1990; Lawson et al., 1992; Chaing et
al., 1994) found almost no amidolytic activity. Hence the
activation of factor VII (Hagen et al., 1986), a single-chain
protein of 406 residues converted to factor VIIa by cleavage
of a single peptide bond between Arg152 and Ile153, can now
be recognized as the primary event that initiates the coag-
ulation cascade by cleavage of factors X and IX (Nemerson,
1988; Lawson and Mann, 1991; Krishnaswamy, 1992;
Butenas and Mann, 1996; Tuddenham, 1996; Kirchhofer
and Nemerson, 1996). The full enzymatic potential of factor
VIIa requires complexation with TF in the presence of
calcium ions (Nemerson, 1988; Davie, 1995; Rapaport and
Rao, 1995).
Factor VII circulates at very low concentration (10 nM)
and has a short half-life of 2–3 h, whether it is in the
zymogen form or in its activated form, a property unique
among the other vitamin K-dependent coagulation proteases
(Petersen et al., 1995). The elevated level of factor VII leads
to increased risk of coronary thrombosis (Meade, 1983), and
the deficiency of factor VII is associated with either variable
bleeding (Triplett et al., 1985) or thrombotic manifestations
(Tuddenham and Cooper, 1994). Serine proteases (SP) in-
cluding factors IXa, Xa, XIIa, and thrombin have been
reported to activate factor VII in vitro, but precisely which
of these is responsible in vivo remains unknown. It has been
reported (Nemerson and Esnouf, 1973; Sakai et al., 1989;
Nakagaki et al., 1992; Yamamoto et al., 1992; Ruf, 1994;
Edgington et al., 1997) that the factor VIIa/TF complex may
also activate factor VII autocatalytically under physiologi-
cal conditions. Tissue factor pathway inhibitor (TFPI) can
inhibit TF-bound factor VIIa in the presence of factor Xa
(Petersen et al., 1995).
The x-ray crystal structure of the factor VIIa/TF complex
is available (Kirchhofer et al., 1995; Banner et al., 1995,
1996; Banner, 1997). These coordinates were used to create
a model for the factor VIIa light chain in solution. The
amino acid sequence of the light chain that contains the Gla
domain and two EGF domains is given in Fig. 1, along with
the domain definitions. Molecular dynamics simulations,
successfully applied in previous studies of other coagulation
proteins (Hamaguchi et al., 1992, Li et al., 1995, 1996,
1997; Perera et al., 1997, 1998), can yield atomic-level
information about the solution structure of factor VIIa in its
TF-free form. (Hereafter, we refer to it as TF-free solution.)
Moreover, this TF-free solution structure will serve as a
valuable template for predicting the structural changes as-
sociated with the formation of the factor VIIa/TF complex
and organizing mutational data. Our main focus in the
present work is on the structural changes in the Gla and
EGF1 domains due to calcium binding and TF association
in the EGF1 domain. We will discuss the lipid binding
properties of the Gla domain by examining the properties of
the calcium-Gla network, the -loop structure, and the
spatial arrangements of other potential lipid-binding resi-
dues. The function of the calcium ion bound to the EGF1
domain is studied by removing it and comparing the result-
ing structure, determined by simulation, with the predicted
solution structure in the presence of this calcium. Although
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our primary focus is on the Gla-EGF1 fragment of factor
VIIa, inclusion of the EGF2 domain is, however, essential
for providing a realistic environment for the EGF1 domain.
COMPUTATIONAL PROCEDURE
Model construction and simulation protocol
The initial structures of the model protein (residues 1–142) were derived
from the crystallographic coordinates of the factor VIIa/TF/Ca2 fragment
(pdb entry  1dan). Crystallographic water molecules within 5 Å of any
protein atom were included, and all of the calcium coordinates assigned in
the crystal configuration were preserved in the initial structure. Necessary
hydrogen atoms were added to the x-ray crystallographic structure, fol-
lowed by energy minimization of the side chains, using a distance-depen-
dent dielectric function (500 steepest descent steps followed by 10,000
conjugate gradient steps).
The protein (along with the crystallographic water molecules and the
calcium ions) was then solvated in a box of water molecules so that the box
boundaries are at least 12.5 Å away from any protein atom. Water mole-
cules used in the solvation of the protein for which the oxygen or hydrogen
atoms were found to be within 2.0 Å of any atom in the protein were
excluded. The central simulation box contained 142 residues of the light
chain of factor VIIa, 16,485 water molecules, and 10 calcium ions. In
addition to the eight calcium ions found near the Gla and EGF1 domains
of the x-ray crystal structure of TF-bound factor VIIa, two calcium ions
were introduced as free nonbound counterions. The two calcium counter-
ions did not coordinate with any of the protein residues at any time during
the simulation. The simulation system was thus electrically neutral. The
total number of atoms in this box was 51,939. In the first step, only the
added water molecules were energy minimized at constant volume (10,000
conjugate gradient steps), then all of the water molecules were subjected to
energy minimization (another 10,000 conjugate gradient steps), and finally,
the whole system was energy minimized (10,000 conjugate gradient steps).
The system was subsequently subjected to a slow heat-up procedure to
bring the temperature of the system to 300 K. After 25 ps of a constant
volume/constant temperature simulation, the system was reminimized
(20,000 conjugate gradient steps). After another heat-up run of 10 ps to
bring the temperature back to 300 K, a constant temperature/constant
volume MD run was performed for 25 ps. Finally, a constant pressure/
constant temperature protocol was adopted to simulate 600 ps of dynamics.
In the present study, we used the second generation of AMBER force
field (Cornell et al., 1995) in conjunction with the particle mesh Ewald
method (Essmann et al., 1995) to accommodate long-range interaction in
all of the solution simulations. The trajectory calculations were done with
AMBER version 4.1 (Pearlman et al., 1995). The time step was 1 fs, with
the nonbonded interactions updated at every step in all simulations. This
choice of updating nonbonded interactions and the periodical removal of
the translational and rotational motions of the center of mass (every 2.5 ps)
help prevent artifacts, such as the observation of a “flying ice cube”
(Harvey et al., 1998).
The role of the calcium ion bound to EGF1 domain was studied by
removing it from the predicted TF-free solution structure of the light chain
of factor VIIa. A simulation led to comparison of the TF-free solution
structures with and without this ion. The removal of the calcium ion from
the EGF1 domain was achieved as follows. As this ion was removed from
the vicinity of the EGF1 domain, another calcium ion was created at an
appropriate distance from the peptide to maintain the consistency in the
constituents of the simulation box. First, a particle having Lennard-Jones
parameters ( and ) similar to the ones used for calcium ions in the present
study was created at a location at least 15 Å from any protein atom. This
particle was grown while fixing  at Ca and incrementally changing ,
from 10% of Ca initially, to full value. The creation of the new particle
was completed during a 30-ps dynamical trajectory. During the next 100 ps
of the trajectory, the charge of the calcium ion bound to EGF1 was reduced
stepwise from its full value (2e) to zero while an equivalent amount of
charge was added to the new particle. This process converts the new
particle to a calcium ion and the calcium ion initially bound to the EGF1
domain to an uncharged particle. The subsequent stepwise reduction of 
from its original value to zero over 100 ps removes this particle from the
simulation box. This procedure removes the calcium ion bound to EGF1
FIGURE 1 The amino acid se-
quence of the segment of the factor
VIIa light chain used in the present
study. The domain definitions are as
follows: Gla domain, residues 1–35;
connecting region between the Gla
and EGF domains, residues 36–45;
EGF1 domain, residues 46–82; con-
necting residues between the EGF1
and EGF2 domains, residues 83–85;
EGF2 domain, residues 86–131; con-
necting region between the EGF2 do-
main and the SP domain, residues
132–142. The disulfide loops are also
marked. However, in the text, the res-
idues in the Gla-EGF1 connecting re-
gion are considered to be part of the
Gla domain.
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domain and places its solvated successor in another part of the central
simulation box with no direct interactions with any of the protein atoms.
Finally, a shake-up procedure to improve dynamical sampling was imple-
mented to accelerate the events (if any) following the removal of the
calcium bound to the EGF1 domain. In this procedure, the system was
heated up to 350° K over 25 ps of dynamics, and the temperature was
maintained at 350° K for an additional 25 ps. The temperature was reduced
to 300° K during the next 25 ps of dynamics and was maintained at 300° K
for the remainder of the trajectory calculation (a total of 1.445 ns).
RESULTS AND DISCUSSION
Global aspects of the simulation
Molecular dynamics simulation methods have proved to be
a valuable complementary tool for obtaining molecular-
level information of the protein structures in solution. How-
ever, one must take considerable precautions in predicting
solution structures from dynamical simulations to ensure
that the systems in consideration reach equilibrium. Inade-
quate simulation times and inappropriate methodology for
determination of long-range interactions can lead to diffi-
culties. Thus it is essential to provide testing to achieve
stability. Currently, in addition to the realization of con-
stancy in the potential energy as a measure of the stability of
the system, simulators use RMSDs with respect to the
crystal configuration or to the initial minimized configura-
tion (Hamaguchi et al., 1992; Li et al., 1995; Perera et al.,
1997). Another, more useful calculation for multidomain
proteins is to evaluate the individual RMSDs for each
domain (for example, Gla, EGF1, and EGF2 in the present
case). This procedure can yield information on how partic-
ular domains restructure because of the presence of solution,
absence of crystal contacts, or inclusion/absence of ions.
The RMSDs calculated from the union of domains are
essential for obtaining details of interdomain motion. In Fig.
2, we display the RMSDs of the entire peptide (residues
1–142), the Gla domain (residues 1–35), the EGF1 domain
(residues 46–84), the EGF2 domain (residues 85–131), and
the Gla/EGF1 (residues 1–84) and EGF1/EGF (residues
45–131) unions. We focus on the results of RMSD up to 600
ps because at this time the removal of the calcium ion bound
to the EGF1 domain is initiated (discussed in a later sec-
tion). Smaller fluctuations in all of the values of RMSDs
during the 400–600-ps segment of the simulation ensure the
stability of the system in solution. The displacements of the
backbone atoms of the individual Gla and EGF1 domains
with respect to their x-ray crystal positions remain relatively
small (the final values of the RMSD fluctuate around 0.5 Å
for these two domains). The deviation of the EGF2 domain
with respect to the x-ray crystal structure shows a relatively
larger magnitude (around 1.8 Å) compared to the Gla and
EGF1 domains. This is to be expected, because the EGF2
domain loses a number of contacts with the SP domain, and
the latter is excluded from the present model calculation. On
the other hand, the combined Gla/EGF1 and EGF1/EGF2
domains show somewhat larger magnitudes in their RMSD
values than the individual domains. As has been pointed out
earlier (Hamaguchi et al., 1992), such deviations may arise
because of relative domain motions, even though individual
domains remain relatively near the TF-bound crystal struc-
ture. When the combined three-domain structure is consid-
ered, the net reorganization effect is amplified in the RMSD
curve (RMSD  3.5 Å). The density fluctuations of the
system, found to be small ( 1.04 0.02 g/cc) during the
final 100-ps interval, provide additional support for system
stabilization.
The simulation B-factors, calculated for backbone atoms
by averaging over the 350–600-ps segment of the trajec-
tory, are given in Fig. 3. The general trends show that the
backbone atoms in the TF-free solution structure are rela-
tively stabilized around their average positions, and the
fluctuations around the average positions are on the order of
an angstrom. The residues that exhibit significantly larger
movements through their B-factors compared to the major-
ity of the residues, with the exception of His84, are glycine
residues (58, 59, and 107). None of these residues, including
His84, have H-bonds with the other residues. Likewise, none
were found to have crystal contacts with any other residue
in factor VIIa (both light and heavy chains taken together)
FIGURE 2 Root mean square deviations (RMSDs) of the backbone
atoms, calculated with respect to the positions of atoms in the x-ray crystal
configuration of the factor VIIa/TF complex. In addition to residues 1–142,
which comprise all three domains (Gla, EGF1 and EGF2), the RMSDs of
individual Gla, EGF1, and EGF2 domains are included. The RMSDs
calculated for combined domains, Gla/EGF1 and EGF1/EGF2, are dis-
played to probe possible interdomain separations.
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or with TF (when factor VIIa is bound in the crystal
configuration).
The final predicted TF-free solution structure was
checked using the program PROCHECK (Laskowski et al.,
1993) to evaluate the “goodness” of the geometrical entities
such as bonds, angles, and dihedral angles in the average
molecular structure of the solution protein when compared
with those found in the crystal. The PROCHECK compar-
ison showed no major discrepancies. Although Lys32 of the
x-ray crystal structure of TF-bound factor VIIa falls in the
disallowed region according to the values for its Phi/Psi
angles, the angles associated with this residue in the TF-free
solution structure are found within the acceptable values.
Gla domain
The Gla domain and the following hydrophobic stack have
been shown to be important for the optimal interaction
between factor VIIa and TF (Persson, 1996). Likewise, it
has been suggested that this fragment is important for mac-
romolecular substrate recognition (Martin et al., 1993). The
Gla domain of factor VII contains 10 Gla residues. Of the
nine calcium ions found in the x-ray crystal structure of
TF-bound factor VIIa, seven are present near the Gla region.
These calcium ions participate in the formation of the Gla-
calcium network. The effect of the calcium ions on the
structure and function of factor VIIa and the affinities of the
calcium binding have been subjected to extensive studies by
several laboratories (Cheung and Stafford, 1995; Persson
and Petersen, 1995; Persson, 1996, 1997; Petersen and
Persson, 1996; Freskgard et al., 1998; Inoue et al., 1996).
Geng and Castellino (1997) studied the lipid-binding prop-
erties of a recombinant chimeric protein in which the Gla
and helical stack domains of human anticoagulant protein C
were replaced by those of human factor VII. They observed
that the chimeric protein maintains the calcium/phospholip-
id-related functions of protein C and suggested, on the basis
of similarity to factor VIIa, that the general calcium ion-
dependent membrane-binding properties are very similar in
the vitamin K-dependent coagulation proteins. However,
the actual degree of affinity of lipid binding may depend on
the sequence specificity found in different VKD proteins.
For example, protein C and factor VII do not contain a Gla
residue at position 33, and they both have low affinity
toward membranes (McDonald et al., 1997a,b).
We compare the Gla domain (residues 1–45) solution
structure with that of the factor VIIa/TF in crystal (Fig. 4).
The displacements, on average, are found to be relatively
small, even for the side chains (the RMSD for the backbone
and all heavy atoms in this domain is 1.40 Å). However,
some change in the backbone dihedral angles associated
with Gla7 and Gla35 occur during the dynamics. The com-
puted B-factors in the TF-free solution simulation for Gla35
(Fig. 3) are normal, whereas they are elevated in the x-ray
crystal structure of TF-bound factor VIIa. Even though
Gla35 does not participate in the Gla-calcium network, the
backbone carbonyl oxygen makes a strong intramolecular
H-bond with the backbone N of Leu39 in the crystal.
Whereas this interaction remains stable in the TF-free so-
lution structure, an additional intramolecular H-bond was
found between the side chains of Gla35 and Lys38 in solu-
tion. Persson and Nielsen (1996) found that if Gla35 is
mutated to Asp, Gln, or Val, the resulting variant has a
lower affinity for TF measured by surface plasmon reso-
nance. However, the mutation Gla35-Glu did not affect TF
binding (Persson and Nielsen, 1996). A closer look at the
TF-bound structure reveals that Gla35 is situated at a dis-
tance sufficient to form a salt bridge with Lys165 in TF.
Gla35 is found to be solvent exposed in both the x-ray
crystal structure of TF-bound factor VIIa (156 Å2) and the
TF-free solution structure (147 Å2). These values are larger
than the solvent-accessible area of other Gla residues, and
hence one can reasonably assume that there is potential for
a salt bridge of Gla35 in factor VIIa with TF that enhances
the association of factor VIIa/TF complex.
FIGURE 3 Experimental (for x-ray crystal factor VIIa/TF: ——) and
calculated (for factor VIIa solution: – – –) B-factors of backbone atoms (N
(top), C (middle), and carbonyl C (bottom)) of the residues (1–142). The
domain boundaries are indicated by vertical lines.
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Several of the calcium ions moved somewhat closer to
Gla residues, forming stronger ionic bonds with them once
introduced to the solution (for example, Ca-3 and Ca-9).
However, no major restructuring in the Gla-calcium net-
work (Table 1) is observed to be due to solvation. Most of
the crystallographic water molecules remained coordinated
to calcium ions during our simulations, emphasizing the
stability of those water molecules in the structure determi-
nation. The N-terminus Ala1 network is also preserved
during the TF-free solution simulation (Table 2). In bovine
prothrobin fragment I (BF1), this network was recognized to
be responsible for the formation of the -loop that under-
goes the required folding for lipid binding in the presence of
calcium ions (Welsch and Nelsestuen, 1988). Taken to-
gether, the stability in the Gla-calcium network and the
conservation of both the Ala1 network and -loop in solu-
tion indicate that lipid-binding properties similar to BF1 can
be expected for the factor VII/Ca complex, even in the
absence of TF.
Residues Lys18, Arg36, and Ser43 in the Gla domain are
found to be in the close vicinity of TF in the crystal
configuration (3.2 Å) and in fact, several of the side-chain
atoms of these residues are close enough to make strong
H-bonds with side chains of the residues in TF. For exam-
ple, NH1 of Arg36 is within 2.7 Å of OG of Ser163 in TF.
This interaction site is in close vicinity to the possible Gla35
(in factor VII) and Lys165 (in TF) interaction site discussed
above. In the TF-free solution structure, both Gla35 and
Arg36 are found to have large solvent accessibilities, indi-
cating their availability for possible H-bonds when TF
comes in contact with factor VII. However, Lys18 is intrado-
main H-bonded to Leu13 in both TF-bound crystal and
TF-free solution configurations. On the other hand, Arg36
has an intradomain H-bond to Asp33 only in the crystal
configuration, whereas Ser43 does not possess intradomain
H-bonds in either structure. The observed intradomain H-
bonds of Lys18 in the TF-free solution structure may com-
pete with the propensity of this residue to form H-bonds
with TF residues. It is interesting to note that no mutation
with severe clinical manifestations has been found so far in
the factor VIIa Gla domain, although there is an interesting
heterozygous mutation (Gla16-Lys) (Tuddenham and
Cooper, 1994; Tuddenham et al., 1995; Cooper et al., 1997).
EGF1 domain
Several residues of the EGF1 domain found to directly
interact with TF have been shown to be substantially re-
sponsible for factor VIIa/TF affinity, using mutational anal-
ysis of factor VIIa (Kelly et al., 1997). Because the present
simulation is performed in the absence of TF, comparison of
the TF-free solution structure to that of TF-bound crystal
may help one understand the consequences of the removal
of TF. In other words, observed structural changes (if any)
in factor VIIa may be partially attributed to the association
with TF. The RMSD values corresponding to the EGF1
domain indicate that the backbone atoms do not undergo
appreciable structural changes when solvated (and separated
from) the TF-bound crystal. For comparison, we display
(Fig. 5) the TF-free solution structure of EGF1 domain and
the superimposed backbone structure of the same domain in
the TF-bound crystal. As can be seen from the figure, the
backbones align quite well, indicating that the changes in
the secondary structure are minimal. It thus appears that the
TF association does not cause significant secondary struc-
tural changes in the EGF1 domain.
Factor VII contains two Gla-independent calcium-bind-
ing sites (as do factors IX and X and protein C). One of
these sites is found in the EGF1 domain of factor VII.
Protein C and factor X contain an aspartic acid residue in
the first EGF domain that is postribosomally hydroxylated
to erythro--hydroxyaspartic acid. The analogous residue is
partially hydroxylated in factor IX. A consensus sequence
that appears to be required for the modification has been
proposed (Thim et al., 1988). Even though factor VII has the
consensus sequence in its EGF1 domain, neither plasma-
derived or recombinant factor VII has been shown to con-
FIGURE 4 Comparison of the final TF-free solution structure (600 ps)
of the Gla domain of factor VIIa residues 1–45 with that of the factor
VIIa/TF crystal complex. The backbone ribbons are used to represent the
secondary structure (solution: light band; crystal: line ribbons). The two
structures were aligned using the best fit of the backbone atom positions.
Changes in the secondary structure are essentially indistinguishable.
Amino acid residues are represented, only for the solution structure, by
lines, and calcium ions are represented by dark circles. The -loop, which
is thought to participate in lipid interaction, is clearly visible at the base of
the structure.
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tain erythro--hydroxyaspartic acid at position 63 (Thim et
al., 1988). This modification, however, does not appear to
affect calcium binding (Selander-Sunnerhagen et al., 1992;
Sunnerhagen et al., 1993, 1995) in EGF1 of factors IX and
X. Because calcium binding involves mostly the residues in
the Gla-EGF1 connecting region, we will defer a discussion
on details of the calcium binding to a subsequent section.
It has been found that the naturally occurring mutation
Asn57Asp in the EGF1 domain (Berube et al., 1992) affects
the folding of this domain and subsequently decreased cel-
lular secretion of mutant factor VII. The mutant protein does
not bind TF and is therefore present in an apparently bio-
logically inactive form (Leonard et al., 1998). Furthermore,
the natural mutation Arg79-Gln in the EGF1 domain may
reduce the affinity for TF binding (O’Brien et al., 1994;
Takamiya et al., 1995). The side chains for all EGF1 resi-
dues in the TF-free solution structure are displayed in Fig.
5. Residues Asp57 and Arg79 are represented by thicker
sticks in Fig. 5. The residues Lys62, Gln64, Ile69, Phe71, and
Arg79 show significant impact on TF binding in the alanine
scanning mutagenesis experiments on factor VII (Dickinson
et al., 1996; Dickinson and Ruf, 1997). Analysis of the
TF-bound crystal structure shows that residues Lys62, Gln64,
Leu65, Ile69, Cys70, Phe71, Cys72, Leu73, Pro74, Glu77, Gly78,
and Arg79 are either in close contact with or in the near
vicinity (within 4 Å) of TF residues (Banner et al., 1996).
These residues are somewhat confined to a planar surface
(base of Fig. 5), which prevents Asn57 from directly partic-
ipating in TF binding in the solution structure. This residue
is positioned in a critical turn and thus may be essential for
proper folding of the EGF1 domain (Leonard et al., 1998).
It is also noteworthy that Asn57 is conserved in most EGF1
domains except protein S and protein C. In fact, the strong
intradomain H-bond found between Asn57 and Cys81 in the
TF-bound crystal structure of factor VIIa is preserved dur-
ing the entire solution simulation. On the other hand, Arg79
is found to be directly involved in TF binding in the x-ray
crystal configuration. This residue is highly solvent acces-
sible (solvent-accessible area 212 Å2) in the TF-free solu-
tion structure and makes no intramolecular H-bonds with
any other residue. As ecxpected, almost all of the residues
that participate in the TF binding in the TF-bound crystal
configuration are found to be highly solvent accessible in
the TF-free solution structure.
It is of interest whether significant side-chain movements
in the interface of the EGF1 domain with TF (described
above) occur because of TF binding to this interface. We
can analyze the side-chain movement of the interface of the
EGF1 domain with TF by comparing the B-factors calcu-
lated for the heavy atoms of the side chains with the corre-
sponding B-factors from x-ray experiment. The B-factors of
the side chains in the TF-free solution, in general, are
somewhat smaller than the TF-bound crystal form, and this
follows a similar observation for backbone atom B-factors
given in Fig. 3. As evident from Fig. 6, some of the residues
(Lys62, Gln64, Leu65, Phe71, Leu73, and Arg79) that were in
close contact with or in the vicinity of TF show larger
TABLE 1 Ca2-Gla interactions (dCa-Gla ≤ 3.0Å) for the crystal structure of factor VIIa/TF complex (top line) versus the TF-free
solution structure of factor VIIa (bottom line)
Gla Water Other Total
Gla3 06 07 14 16 19 20 25 26 29
1234 1234 1234 1234 1234 1234 1234 1234 1234
0101 0100 0011 2 (2) 7
Ca-3 0101 1000 0100 0011 1 7
1100 0010 1000 0001 3 (3) 8
Ca-4 1100 0010 1000 0001 3 (3) 8
1000 1000 1010 1001 NO 1 7
Ca-5 1100 1000 1010 1001 NO 1 8
1001 1100 0011 1 (1) 1 8
Ca-6 1001 1100 0011 1 1 8
0110 0110 1 (1) 5
Ca-7 0110 0110 3 7
1010 NO 2
Ca-8 1010 6 8
1000 1010 NO 4
Ca-9 1010 1010 4 8
The results were averaged over the last 20 ps of the trajectory for the solution structure (600 ps). The number of water molecules given in parentheses
represents the crystal water. (NO  no water molecules found in the crystal configuration.)
TABLE 2 Comparison of the Ala1-N network of the solution
structure of factor VIIa in its TF-unbound form with the factor
VIIa/TF in the crystal
Crystal Ala1-N Gla20-OE4 2.5 163
Ala1-N Gln21-O 3.0 156
Ala1-N Gla26-OE4 2.8 155
Ala1-N Ca-4 4.34
Ala1-N Ca-5 3.85
Solution Ala1-N Gla20-OE4 2.8 173
Ala1-N Gla16-O 2.7 152
Ala1-N Gla26-OE4 2.9 159
Ala1-N Ca-4 4.42
Ala1-N Ca-5 4.07
The distances and angles were averaged over the last 20 ps of the simu-
lation. The cutoff distance and angles were 3.0 Å and 115°, respectively.
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B-factors in TF-free solution and, certainly, some of these
B-factors are larger than the experimentally reported values
in the TF-bound crystal. Except in the case of Lys62 and
Arg79, which are ionic side chains, the other residues may
not be extended very much into water because of the hy-
drophobic nature of these residues. Because in binding with
TF these residues were somewhat extended, in solution they
find it more appropriate to cluster with the other hydropho-
bic residues in the aqueous environment.
Carbohydrate chains attached to the O-glycosylation sites
(Ser52 and Ser60) in the EGF1 domain of factor VII in the
TF crystal complex were not included in our present TF-free
solution structure calculation. Two serine residues in the
EGF1 domain of factor VIIa, Ser52 and Ser60, are reported
to support carbohydrate linkages (Bjoern et al., 1991). A
trisaccharide, or a truncated form of a longer carbohydrate,
is O-glycosidically linked to Ser52 of human factor VIIa
(Bjoern et al., 1991). There are similar reports of carbohy-
drate attachment at this position for bovine factors VII and
IX, human factor IX, and human and bovine protein Z
(Nishimura et al., 1989). Ser60 contains an O-glycosidically
linked fucose fragment (Bjoern et al., 1991; Harris et al.,
1991). The direct biological function of the carbohydrate
attachment is as yet unknown, but mutations at Ser52 and
Ser60 (by Ala) show reduced clotting activity in factor VII
(Iino et al., 1998). Iino et al. (1998) also found indistin-
guishable changes in TF-dependent and TF-independent
amidolytic activity for mutants compared to the wild type.
The possible glycosylation site of the nearby Ser53 residue,
in both TF-bound crystal and TF-free solution, is directed
somewhat toward the interior of the protein and hence is
less accessible for glycosylation. Furthermore, in both TF-
free solution and TF-bound crystal, we find that the side
chain of Ser53 forms two intramolecular H-bonds as op-
posed to a single intramolecular H-bond found in each Ser52
and Ser60, thus reducing the possibility of forming the
carbohydrate link.
EGF2 domain
The focus of the current work is on the Gla-EGF1 domains.
The EGF2 domain, however, was included in the present
calculation to provide a more realistic environment, espe-
cially for the EGF1 domain. Changes that we find in the
TF-free solution structure of EGF2 domain must be due to
loss of TF contacts, but also to lack of EGF2-SP domain
contacts. Thus caution is warranted in interpreting the EGF2
simulation structure. That aside, we find that whereas the
EGF2 RMSD is somewhat larger (Fig. 2) than the individual
Gla and EGF1 domain RMSDs, the long axis of the peptide
Gla-EGF1-EGF2 does not change appreciably during the
simulation. Similarly, the overall fold of EGF2 is main-
tained (Fig. 7), although some change occurs in the con-
necting segments between EGF1 and EGF2 (residues 85–
93) and in the segment 103–111. Only a few of residues of
FIGURE 5 Comparison of the final TF-free solution structure (600 ps: light band) of the EGF1 domain of factor VIIa with that of the factor VIIa/TF
x-ray crystal complex (line ribbons). The least-squares fit of the backbone atoms was used for the alignment. Side chains are displayed for the solution
structure. The two residues (Asn57 and Arg79), which are involved in TF binding, are especially marked. All of the residues that participate in TF binding
are seen at the base of the figure (along with Arg79).
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the EGF2 domain make direct TF contacts, and apparently
all are in the segment 85–93. Neither TF residues nor SP
domain residues make crystal contacts with the residues in
the segment 103–111. Retention of the overall fold of this
domain is not surprising, because it has been shown that the
epidermal growth factor-like domains of factor VIIa remain
stable under high guanidine hydrochloride concentrations
and at elevated temperatures (Freskgard et al., 1998).
Calcium binding to the EGF1 domain
The calcium binding site in EGF1 extends from the N-
terminus residues of the EGF1 domain to residues interior to
the EGF1 domain. It has been suggested that the calcium
binding to the EGF1 domain has no direct effect on contacts
with TF residues (Persson and Petersen, 1995), but that the
overall docking is enhanced through a Gla-EGF1 orienta-
tion stabilized by calcium binding. Kelly et al. (1997) ob-
served significant reduction of TF binding due to Gly, Ala,
and Glu replacements of Asp46. The loss of function was
argued to be due to increased flexibility of the Gla domain
relative to the EGF1 domain. Structure analysis of the
relative orientation of Gla and EGF1 domains in factor X,
using combined NMR-small angle x-ray scattering tech-
niques, has shown that the relative orientations of the Gla
and EGF1 domains depend on calcium binding to the latter
domain (Sunnerhagen et al., 1995). In Fig. 8 a, we display
the Gla/EGF1 domains and the calcium ion present near the
junction of these two domains. The calcium ion in the x-ray
crystal structure of factor VIIa/TF was found to be octahe-
drally coordinated with six oxygen ligands from Asp46:
OD2, Gly47:O, GLN49:OE1, Asp63:OD1 and OD2, and
Gln64:O. In this “pseudo-octahedral” configuration, four
corners are occupied by oxygen atoms, and the fifth corner
by the Asp63 carboxylate. The sixth corner was assumed to
be occupied by a water molecule. Nuclear magnetic reso-
nance experiments (Sunnerhagen et al., 1995) revealed that
the analogous residues in the EGF1 domain of factor X were
in contact with the calcium ion. No contacts in the TF-free
solution simulation structure were lost compared to the
TF-bound x-ray crystal configuration (see Fig. 8 b), and in
fact, two additional water molecules were accommodated in
its coordination sphere in the TF-free solution structure.
These water molecules remained rather immobile during the
FIGURE 6 Experimental (for x-ray crystal factor VIIa/TF: E) and calculated (for TF-unbound factor VIIa in solution: f) B-factors of side-chain heavy
atoms of the residues (48–84) in the EGF1 domain. Residues bound to (or in the vicinity of) TF in the TF-bound crystal configuration of factor VIIa are
labeled.
106 Biophysical Journal Volume 77 July 1999
trajectory calculation; however, one of the carboxylate ox-
ygen atoms of Asp63 moves in and out of the coordination
shell of the EGF1-bound calcium ion. In fact, the solution
coordination shell of calcium can be recognized as a “pseu-
dopentagonal bipyramid,” especially in the situation where
only one Asp63 oxygen participates in the coordination of
calcium (see Fig. 8 c). In this structure, calcium is sur-
rounded by a pentagon composed of Gly47:O, Gln49:OE1,
Gln64:O, and the oxygen centers from the two water mole-
cules at the vertices. Asp46:OD2 and Asp63:OD1 can be
found as apical ligands. When both carboxylic oxygens are
in the coordination shell, the structure is still “pseudopen-
tagonal bipyramidal,” with Asp63 as a double ligand at an
apical site (see Fig. 8 d).
The electrostatic potential surface around the calcium ion
bound to the EGF1 domain is highly electronegative (cir-
cled in Fig. 9 a). The figure was created (GRASP; Nicholls
et al., 1993) after removal of the calcium ion from the
equilibrated solution structure for which calcium was
present in the dynamical steps. This region is approximately
neutral (in charge) with the calcium ion in place (Fig. 9 b).
The calcium ion from the EGF1 domain was removed in
the latter part of our simulation (after 600 ps) to assess its
structural importance. The response of the system due to
removal of the calcium ion bound to the EGF1 domain can
be viewed directly from the changes observed in the
RMSDs after 600 ps (Fig. 2). No observable changes appear
to be associated with the individual Gla and EGF2 domains
due to removal of this calcium ion. A significant increase in
the RMSD (from 0.5 to 1.5 A) of EGF1 is observed in the
latter part of the trajectory, indicating some restructuring in
the EGF1 domain. The RMSDs for the EGF1 domain shown
in Fig. 2 were calculated by using residues 46–84. To
obtain further information about why the total RMSD is
larger than before removal of the calcium ion and which
residues contribute to the enlarged RMSD, we have exam-
ined the RMSDs of the individual residues in the EGF1
domain. The reference system was the crystal configuration.
These RMSDs averaged over 25 ps (the segment between
570 and 600 ps for the system with calcium bound to the
EGF1 domain and the segment between 1420 and 1445 ps
after removal of that calcium) were displayed against the
residue numbers in Fig. 10. The content of the figure was
made similar to figure 5 of Muranyi et al. (1998) to facilitate
the direct comparison of simulation and experiment, and
hence the alignment was done using residues 49–84. Note
that this selection is different from the original selection of
residues 46–83 used in the calculation of total RMSD of the
EGF1 domain in Fig. 2. In the work of Muranyi et al.
(1998), the solution structure of a synthetic N-terminal
EGF-like domain from human factor VII was determined in
the absence of calcium ions, using 1H NMR spectroscopy.
Comparison of the simulation and experiment (figures 9 and
5 of Muranyi et al., 1998) shows that the simulation cap-
tures all features of major structural rearrangement due to
the loss of calcium observed in experiment. The EGF1
domain structure is changed only in the regions for which
the calcium ion had contacts, and the changes are found to
be significant only for a few residues at the N-terminus of
the EGF1 domain. Comparison of the calcium bound struc-
ture (dotted line) to the calcium removed structure (solid
line) results in the observation that residues around Gln64
FIGURE 7 Comparison of the final TF-free solution structure (600 ps) of the EGF2 domain of factor VIIa (light band) with that of the factor VIIa/TF
x-ray crystal complex (line ribbons). The least-squares fit of the backbone atom positions was used for the alignment. Side chains are displayed for the
solution structure.
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FIGURE 8 (a) The final TF-free solution structure (600 ps) of the Gla/EGF1 domains of factor VIIa. All of the calcium ions in the Gla and EGF1 regions
are displayed along with the hydrophobic residues (Phe4, Leu5, and Leu8) in the Gla domain that are thought to interact with phospholipid upon lipid
binding. (b) The residues in the EGF1 domain solution structure that coordinate with the calcium ion. The coordinated water molecules are not shown. (c)
The solution “pseudo-pentagonal pyramidal” structure of the calcium ion coordinated to the EGF1 domain. Oxygens of the two water molecules (dark
circles and unmarked), along with O:Gln64, OE1:Gln49 and O:Gly47, form the pentagon, and OD1:Asp63 and OD2:Asp46 are located at the apical positions.
The calcium ion is at the center. (d) A frequently populated coordinate shell during the simulation. In addition to the atoms found in c, OD2:Asp63 also
participates in the coordination of calcium.
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have slightly perturbed backbone positions. Interestingly, a
majority of the residues in this domain help maintain sec-
ondary structure when the calcium ion is removed. This
observation is emphasized from the backbone C superim-
position shown in Fig. 11 for the TF-bound crystal and the
two TF-free solution structures.
Before removal of the calcium bound to the EGF1 do-
main, the observed RMSDs for the combined Gla/EGF1
domains and EGF1/EGF2 domains are somewhat larger
than RMSDs for the individual domains (see Fig. 2). The
larger RMSDs suggest possible interdomain motions, espe-
cially in the case of Gla/EGF1, because the individual
domains display much smaller RMSDs. A reasonable check
for the possibility of interdomain motion can be obtained by
viewing the snapshots of the backbone structure after align-
ing them. In Fig. 12, we display the backbone ribbon
structures for the TF-bound crystal (dark band) and the
TF-free solution before (lighter band in Fig. 12 a) and after
(lighter band in Fig. 12 b) the removal of calcium bound to
the EGF1 domain. Because the EGF1 domain is common
for both the Gla/EGF1 and EGF1/EGF2 combined domains,
the EGF1 domain (residues 46–84) is used for the align-
ment. Although there is not a perfect match of each domain,
the factor VIIa domains in solution are spatially close to
those in the factor VIIa/TF crystal. This spatial correspon-
dence of the three domains leads to the conclusion that there
is no significant alteration in the length of the light chain of
factor VIIa along the long axis through interdomain move-
ment due to the association with TF. This is in good agree-
ment with the experimental finding (using x-ray and neutron
scattering on the factor VIIa in TF-free and TF-bound forms
in solution) that in solution, factor VIIa has an extended or
elongated domain structure, providing a large surface area
for interaction with TF to form a high-affinity complex
(Ashton et al., 1998). It is interesting that the RMSDs of TF
FIGURE 9 Electrostatic potential surfaces calculated for residues 1–84
in the TF-free solution structure. The program GRASP (Nicholls et al.,
1993) was used to construct the surface. All calcium ions except the one
bound to the EGF1 domain are present in the surface construction. (a) The
calcium ion was removed (600 ps). The dark red patch in the middle
(circled) represents the electronegative region to which the calcium ion is
bound. (b) With the calcium in place, the electrostatic potential (in the
circled region) shows neutrality.
FIGURE 10 Backbone atom displacements of the EGF1 residues. The
deviations were calculated with respect to the crystallographic positions.
Calcium free (——) and EGF1 bound calcium (– – –). In the calculation of
backbone RMSDs, the systems are aligned with residues 49–84 to facil-
itate comparison with experiment (Muranyi et al., 1998).
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coordinates in crystal (Harlos et al., 1994; pdb entry 
1boy), when aligned with TF coordinates in the factor
VIIa/TF complex (pdb entry  1dan), are 1.37 Å (heavy
atoms) and 0.86 Å (backbone atoms). Thus we might pre-
dict minimal restructuring of the components of the factor
VIIa/TF complex during the protein-protein complexation.
However, once aligned using the EGF1 domain residues,
the positions of the backbone atoms of the Gla domain
residues in solution are shifted by 3–4 Å, on average,
from the crystal positions toward the space occupied by TF.
Still, the orientation of the Gla domain in solution remains
rather parallel to that of the TF-bound crystal form. Mean-
while, the backbone atoms of the residues in the EGF2
domain in solution (once the EGF1 residues are aligned)
move 5–6 Å, on average, away from the crystal positions.
On the other hand, removal of the calcium brings much
larger changes to the Gla EGF1 orientation (Fig. 12 b). Both
RMSD (Fig. 2) and the backbone ribbon diagram (Fig. 12 b)
convincingly illustrate such large deviations. In the pictured
alignment, the backbone atoms of the Gla domain residues
in solution show 15–20-Å deviations from the crystal posi-
tions. However, the deviations in the backbone atoms of the
EGF2 domain residues are rather comparable with those
found in solution with the EGF1-bound calcium intact.
Even after the removal of the EGF1-bound calcium ion,
spatial arrangement of the three domains predicts that the
light chain of factor VIIa shows only 2–3% reduction in
its chain length compared to that of TF-bound crystal.
The Gla domain is thought to be responsible for lipid
binding (Pollock et al., 1988; Wildgoose et al., 1992). The
interaction of the Gla domain with the lipid surface has been
proposed to be via calcium bridging (Nelsestuen, 1988) or
through insertion of hydrophobic residues to the lipid sur-
face (Ellison and Castellino, 1997). Although there is a
slight Gla-EGF1 reorientation in solution with TF absent,
the spatial arrangement that may be provided for lipid
binding appears similar in TF-free solution and TF-bound
crystal structures. A major spatial realignment of the Gla
and EGF1 domains would be required in the case for which
the EGF1-bound calcium is absent, to bring the two do-
mains into an orientation suitable for both TF and lipid
binding. Fig. 12 emphasizes that the calcium ion bound to
the EGF1 domain is critical for bringing the two domains
(Gla and EGF1) into the correct orientation for factor VII’s
TF binding in solution.
We do not find direct domain-domain interactions via
H-bonding or salt bridges in the predicted TF-free solution
structure or in the TF-bound x-ray crystal structure. How-
ever, the two neighboring domains are connected via a
segment of amino acid residues. For the Gla and EGF1
domains, the segment of residues 36–45 acts as the con-
necting region, whereas for the EGF1 and EGF2 domains
residues 84–86 provide this function. The amino acid res-
idues found in the connecting region can make H-bonds
individually with domains that they connect. Depending on
the length of the connecting region, this situation can confer
a flexibility on the domain alignments.
In the present work we have assessed the importance of
the calcium ion bound to the EGF1 domain in TF binding.
Furthermore, comparison of the TF-free solution structure
with the TF-bound crystal was used to understand how the
EGF1 domain responds to TF binding. A complete picture
of the response of factor VIIa to the interaction with TF may
FIGURE 11 Alignment of the C positions of the EGF1 domains for the TF-bound crystal (thin dark line in both panels), TF-free solution (thick lighter
line), TF-free solution without calcium (thick dark line). The TF-free solution structures were aligned with residues 49–84 of the TF-bound crystal structure.
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be obtained by including all domains of factor VIIa in the
simulation; this is currently under way in our laboratory.
CONCLUSIONS
We have used molecular dynamics simulations to estimate
the solution structure of the light chain of factor VIIa in the
absence of TF. The domain structures (Gla, EGF1, and
EGF2) are found to be very similar to the corresponding
domains of the factor VIIa/TF complex of the x-ray crystal
form. No significant change in the chain length along the
long axis of factor VIIa compared to its activated, tissue
factor-bound form is observed during the 600-ps simulation.
This is in good agreement with experimental findings (Ash-
ton et al., 1998), for which the solution domain structure of
factor VIIa appears extended. However, we find relative
domain-domain movements for both Gla/EGF1 and EGF1/
EGF2 domains. Furthermore, no direct interdomain salt
bridges or H-bonds are found in the TF-free solution
structure.
The Ala1 network (in the formation of -loop) and the
calcium-Gla network found in the x-ray crystal configura-
tion of TF-bound factor VIIa are preserved in the solution
structure of TF-free factor VIIa. The features of the Gla
domain solution structure of factor VIIa are very similar to
those found in the solution structure of the Gla domain of
BF1. It appears reasonable that the Ala1 network in BF1 is
responsible for the phospholipid binding conformation of
the -loop (residues 1–11), with the calcium-Gla network
providing the correct folding for lipid binding. Similarities
observed in the above networks of factor VIIa and BF1
indicate similar mechanisms for lipid binding.
The coordination of the calcium ion to protein atoms
present near the connecting region of the Gla and EGF1
domains to the amino acid residues in these domains re-
mains unchanged in the solution structure without TF,
whereas the coordination shell that is partially saturated in
the x-ray crystal structure (six bonds) extends its coordina-
tion number to 8 by including two water molecules in the
coordination shell in the solution structure. We find that
removal of this calcium ion leads to only minor structural
changes in the EGF1 domain of the TF-free solution struc-
ture, but the Gla-EGF1 relative orientation is substantially
disturbed. Our simulation results agree well with the exper-
imental finding of minimal structural changes in the EGF1
domain associated with the calcium binding to that domain
(Muranyi et al., 1998). Furthermore, the current simulation
provides a prediction for an altered relative orientation
between the Gla and EGF1 domains resulting from calcium
binding, similar to the finding of Gla-EGF1 reorientation
for factor X from combined NMR–small-angle x-ray scat-
tering experiments (Sunnerhagen et al., 1995).
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